For Cardioexplorer

heart failure explorer

Heart Failure

Heart Failure is one of the most prominent chronic diseases, affecting 2% of the population. Up to 50% patients treated according to the guidelines deteriorate. Co-morbidities and adverse effects on multiple drugs, result in a complexity which so far have not been mastered. Therefore a new approach, overcoming the limitations of the current guidelines is sought. Biomarkers are an expression of these effects on system level. Our proprietary AI-X-platform uses these markers to derive AI models which allow to optimize the therapy, leading to a significant reduction of hospitalization and death rate.

HeartFailure Explorer is an Artificial Intelligence model based test which supports individual therapy of heart failure

The test provides a risk prediction and therapy proposal which optimizes treatment effect and considers co-morbidities and adverse effects on an individual patient level.

Our beta version of HeartFailure Explorer has been developed together with Prof. Hans-Peter Brunner at the cardiology department, Maastricht University.


Previous therapies

At the present time medical guidelines recommend the following heart failure therapy: ACE inhibitor, b-blocker, eperelone, loop diuretic. If patients do not satisfyingly respond to the therapy, the cardiologist has to alter the dosage of medication in trial and error mode, navigating through a difficult field of different other impacts like adverse effects trough the increased dosage of certain drugs, or conspicuous conflicts with other medication. For those patients residence costs can dramatically increase due to a not appropriate therapy.

First validation

We applied the HeartFailure models also to data of the PROTECT study of the Heart Center, Massachusetts General Hospital Boston. First tests have confirmed the former results. 

Development of a fundamental new therapy for 

heart failure

Since 2018 are we part of the EU, Switzerland and Canton Zurich funded Interreg Project PASSION (official Website

The consortium, consisting of four leading clinics in Europe, medical associations and innovative companies is developing a fundamental new therapy for heart failure. A novel e-health platform will include AI supported diagnostics and therapy guidance, a nurse avatar and serious gaming.